Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Rep Pract Oncol Radiother ; 28(3): 389-398, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37795402

RESUMO

Background: The role of host immune system in carcinogenesis and response to treatment is increasingly studied, including predictive potential of circulating neutrophils and lymphocytes. The objective of the study was to evaluate the prognostic value of pre- and post-treatment neutrophil-to-lymphocyte (NLR) for treatment outcome in patients diagnosed with squamous cell carcinoma of head and neck (HNSCC) treated with definitive chemoradiation. Materials and methods: Electronic medical records of patients were evaluated and NLR was calculated. Cox regression was used to assess the impact of selected variables on overall survival (OS), disease specific survival (DSS), progression free survival (PFS) and distant failure free survival (DFFS). Logistic regression was used to estimate odds ratios of complete response with NLR. Results: 317 patients' records were included in the study. Increases in both pre-and post-NLR were associated with decreased OS in univariable analysis [hazard ratio (HR): 2.26 (1.25-4.07), p = 0.0068 and HR: 1.57 (1.03-2.37), p = 0.035 respectively). Post-NLR remained significant for OS in multivariable analysis [HR: 1.93 (1.22-3.1), p = 0.005] as well as for unfavorable DSS [HR: 2.31 (1.22-4.4), p = 0.01]. Pre-treatment NLR and nodal status correlated with shorter DFFS in multivariable analysis [HR 4.1 (1.14-14), p = 0.03 and HR 5.3: (1.62-18), p = 0.0062, respectively]. Strong correlation of increased both pre- and post-NLR with probability of clinical tumor response (CR) was found [odds ratio (OR): 0.23 (0.08-0.6), p = 0.003, and OR: 0.39 (0.2-0.8), p = 0.01 respectively]. Conclusion: NLR evaluated before and post treatment was a strong predictor of unfavorable treatment outcome and can be used for risk evaluation and clinical decision about treatment and post-treatment surveillance.

2.
J Clin Med ; 12(14)2023 Jul 12.
Artigo em Inglês | MEDLINE | ID: mdl-37510750

RESUMO

Nintedanib is a disease-modifying agent licensed for the treatment of IPF. Data on Polish experience with nintedanib in IPF are lacking. The present study aimed to describe the safety and efficacy profiles of nintedanib in a large real-world cohort of Polish patients with IPF. This was a multicenter, retrospective, observational study of IPF patients treated with nintedanib between March 2018 and October 2021. Data collection included baseline clinical characteristics, results of pulmonary function tests (PFTs), and a six-minute walk test (6MWT). Longitudinal data on PFTs, 6MWT, adverse drug reactions (ADRs), and treatment persistence were also retrieved. A total of 501 patients (70% male) with a median age of 70.9 years (IQR 65-75.7) were included in this study. Patients were followed on treatment for a median of 15 months (7-25.5). The majority of patients (66.7%) were treated with the full recommended dose of nintedanib and 33.3% of patients were treated with a reduced dose of a drug. Intermittent dose reductions or drug interruptions were needed in 20% of patients. Over up to 3 years of follow-up, pulmonary function remained largely stable with the minority experiencing disease progression. The most frequent ADRs included diarrhea (45.3%), decreased appetite (29.9%), abdominal discomfort (29.5%), weight loss (32.1%), nausea (20.8%), fatigue (19.2%), increased liver aminotransferases (15.4%), and vomiting (8.2%). A total of 203 patients (40.5%) discontinued nintedanib treatment due to diverse reasons including ADRs (10.2%), death (11.6%), disease progression (4.6%), patient's request (6.6%), and neoplastic disease (2.2%). This real-world study of a large cohort of Polish patients with IPF demonstrates that nintedanib therapy is safe, and is associated with acceptable tolerance and disease stabilization. These data support the findings of previously conducted clinical trials and observational studies on the safety and efficacy profiles of nintedanib in IPF.

3.
J Pers Med ; 12(7)2022 Jun 30.
Artigo em Inglês | MEDLINE | ID: mdl-35887587

RESUMO

Radical treatment of patients diagnosed with inoperable and locally advanced head and neck cancers (LAHNC) is still a challenge for clinicians. Prediction of incomplete response (IR) of primary tumour would be of value to the treatment optimization for patients with LAHNC. Aim of this study was to develop and evaluate models based on clinical and radiomics features for prediction of IR in patients diagnosed with LAHNC and treated with definitive chemoradiation or radiotherapy. Clinical and imaging data of 290 patients were included into this retrospective study. Clinical model was built based on tumour and patient related features. Radiomics features were extracted based on imaging data, consisting of contrast- and non-contrast-enhanced pre-treatment CT images, obtained in process of diagnosis and radiotherapy planning. Performance of clinical and combined models were evaluated with area under the ROC curve (AUROC). Classification performance was evaluated using 5-fold cross validation. Model based on selected clinical features including ECOG performance, tumour stage T3/4, primary site: oral cavity and tumour volume were significantly predictive for IR, with AUROC of 0.78. Combining clinical and radiomics features did not improve model's performance, achieving AUROC 0.77 and 0.68 for non-contrast enhanced and contrast-enhanced images respectively. The model based on clinical features showed good performance in IR prediction. Combined model performance suggests that real-world imaging data might not yet be ready for use in predictive models.

4.
Otolaryngol Pol ; 75(5): 1-8, 2021 May 12.
Artigo em Inglês | MEDLINE | ID: mdl-34552020

RESUMO

Radiotherapy (RT) for patients with head and neck squamous cell carcinoma (HNSCC) affects vital functions related to the irradiation volume of the head and neck region and, in addition, has a negative impact on social functioning, thereby significantly impairing patients' quality of life (QoL). The aim of this study was to assess changes in the quality of life in patients with head and neck cancer treated with curative RT at 12 months after completion of RT. The aim of this study was to assess the differences between the baseline QoL of patients with early clinical stage HNSCC and at 12 months after curative/radical RT. The prospective clinical study included 92 patients in good general condition (ECOG 0-1 - Eastern Cooperative Oncology Group performance status), without regional or distant metastases, diagnosed with pathomorphologically confirmed early-stage head and neck squamous cell carcinoma treated with definitive RT. All patients participating in the study signed an informed consent form. QoL was assessed using the standard EORTC QLQ-C30 and QLQH&N35 questionnaires. In addition, information on clinical aspects and data relating to socio-demographic factors were obtained from each patient. Statistical analysis was performed using a statistical package (SPSS 17.0). T-test was used for dependent and independent samples. A general linear model was used for repeated measures. Patients' QoL deteriorated significantly after definitive RT. Worse QoL Core-30 scores in patients 12 months after the end of RT, compared with baseline QoL, before the start of RT, were observed in domains such as physical performance, fulfillment of life roles, cognitive functioning, loss of appetite, fatigue and constipation. For the QLQ-H&N35 questionnaires, patients 12 months after the end of RT reported problems in relation to aspects of life such as senses, mouth opening, dry mouth, thick saliva, pain, and weight loss. RT, even in early clinical stage head and neck cancer, has a negative impact on QoL, despite modern treatment techniques.


Assuntos
Neoplasias de Cabeça e Pescoço , Xerostomia , Neoplasias de Cabeça e Pescoço/radioterapia , Humanos , Estudos Prospectivos , Qualidade de Vida , Inquéritos e Questionários
5.
BMC Pulm Med ; 20(1): 122, 2020 May 04.
Artigo em Inglês | MEDLINE | ID: mdl-32366291

RESUMO

BACKGROUND: Pirfenidone is an antifibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). The drug is available for Polish patients with IPF since 2017. The PolExPIR study aimed to describe the real-world data (RWD) on the Polish experience of pirfenidone therapy in IPF with respect to safety and efficacy profiles. METHODS: This was a multicentre, retrospective, observational study collecting clinical data of patients with IPF receiving pirfenidone from January 2017 to September 2019 across 10 specialized pulmonary centres in Poland. Data collection included baseline characteristics, pulmonary function tests (PFTs) results and six-minute walk test (6MWT). Longitudinal data on PFTs, 6MWT, adverse drug reactions (ADRs), treatment persistence, and survival were also collected up to 24 months post-inclusion. RESULTS: A total of 307 patients receiving pirfenidone were identified for analysis. The mean age was 68.83 (8.13) years and 77% were males. The median time from the first symptoms to IPF diagnosis was 15.5 (9.75-30) months and from diagnosis to start of pirfenidone treatment was 6 (2-23) months. Patients were followed on treatment for a median of 17 (12-22.75) months. Seventy-four patients (24.1%) required dose adjustments and 35 (11.4%) were chronically treated with different than the full recommended dose. A total of 141 patients (45.92%) discontinued therapy due to different reasons including ADRs (16.61%), death (8.79%), disease progression (6.51%), patient's own request (5.54%), neoplastic disease (3.91%) and lung transplantation (0.33%). Over up to 24 months of follow-up, the pulmonary function remained largely stable. The median annual decline in forced vital capacity (FVC) during the first year of pirfenidone therapy was -20 ml (-200-100) and during the second year was -120 ml (-340-30). Over a study period, 33 patients (10.75%) died. CONCLUSIONS: The PolExPIR study is a source of longitudinal RWD on pirfenidone therapy in the Polish cohort of patients with IPF supporting its long-term acceptable safety and efficacy profiles and reinforce findings from the previous randomised clinical trials and observational studies.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Fibrose Pulmonar Idiopática/tratamento farmacológico , Adesão à Medicação/estatística & dados numéricos , Piridonas/uso terapêutico , Idoso , Progressão da Doença , Feminino , Humanos , Fibrose Pulmonar Idiopática/cirurgia , Pulmão/fisiopatologia , Transplante de Pulmão/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Polônia , Testes de Função Respiratória , Estudos Retrospectivos , Resultado do Tratamento , Teste de Caminhada
6.
J Clin Pediatr Dent ; 43(4): 281-287, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31094636

RESUMO

Idiopathic solitary cysts have a predilection for long bones and the mandible. Although the origin of these cysts is unclear, the prognosis seems to be good, given proper diagnosis and surgical treatment. A 14-year-old female patient with a bone lesion in the right mandibular ramus was referred to the Department of Pediatric Dentistry at the Medical University of Gdansk, Poland. Due to severe headache lasting two days, the patient had previously undergone magnetic resonance imaging (MRI) examination of the head. A unilocular bone cyst in the mandible was discovered incidentally. Comparison with a previous orthopantomogram (OPG) taken two years earlier for routine dental treatment revealed a clearly visible but smaller bone lesion at the same location. Surgery was carried out in order to achieve bone regeneration. This report documents the importance of careful evaluation and assessment of all radiographs taken, as the lesion could have been diagnosed and treated much earlier, thus lowering the risk of complications.


Assuntos
Cistos Ósseos , Cistos Maxilomandibulares , Doenças Mandibulares , Adolescente , Cistos Ósseos/diagnóstico por imagem , Feminino , Humanos , Cistos Maxilomandibulares/diagnóstico por imagem , Mandíbula , Doenças Mandibulares/diagnóstico por imagem , Radiografia
7.
Arch Med Sci ; 10(6): 1153-9, 2014 Dec 22.
Artigo em Inglês | MEDLINE | ID: mdl-25624853

RESUMO

INTRODUCTION: Radiotherapy (RT) in combination with chemotherapy is a standard of care for patients with head and neck squamous cell carcinoma (HNSCC). The RT is associated with side effects, which impact on quality of life (QoL). Thus, the aim of this prospective longitudinal study was to investigate the impact of RT on the QoL of patients with HNSCC during RT. MATERIAL AND METHODS: From September 2008 to February 2010, 205 patients with locally advanced HNSCC were enrolled. The data pertaining to their QoL were collected using the EORTC QLQ-C30 and the EORTC Head and Neck Module (QLQ-H&N35) and then all items were transformed to a 0-100 scale according to the guidelines of the EORTC. The following clinical factors were chosen to study their potential influence on the QoL; site of primary, clinical stage, and methods of therapy: RT vs. chemoradiotherapy (CRT). Additionally, the sociodemographic factors (age, gender, education, habit of smoking) were studied. RESULTS: Deterioration of almost all scales and items in the QLQ-C30 and QLQ-H&N35 questionnaire were noted at the end of RT. The following factors negatively influenced the QoL: age < 60 years (p < 0.05), female gender (p < 0.05), habit of smoking (p < 0.01), advanced clinical stage (III and IV) (p < 0.05), site of primary (larynx, hypopharynx) (p < 0.01), and CRT (p < 0.01). CONCLUSIONS: Our study showed that RT significantly negatively influenced QoL at the end of the RT course. Additionally, this study demonstrated that age, gender, smoking habit, tumor site, and clinical stage of disease showed a significant effect on the QoL of HNSCC patients during RT.

8.
Contemp Oncol (Pozn) ; 16(1): 16-25, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23788850

RESUMO

AIM OF THE STUDY: Helical tomotherapy is one of the methods of radiotherapy. This method enables treatment implementation for a wide spectrum of clinical cases. The vast array of therapeutic uses of helical tomotherapy results directly from the method of dose delivery, which is significantly different from the classic method developed for conventional linear accelerators. The paper discusses the method of dose delivery by a tomotherapy machine. Moreover, an analysis and presentation of treatment plans was performed in order to show the therapeutic possibilities of the applied technology. Dose distributions were obtained for anaplastic medulloblastoma, multifocal metastases to brain, vulva cancer, tongue cancer, metastases to bones, and advanced skin cancer. Tomotherapy treatment plans were compared with conventional linear accelerator plans. RESULTS: Following the comparative analysis of tomotherapy and conventional linear accelerator plans, in each case we obtained the increase in dose distribution conformity manifested in greater homogeneity of doses in the radiation target area for anaplastic medulloblastoma, multifocal metastases to brain, vulva cancer, metastases to bones, and advanced skin cancer, and the reduction of doses in organs at risk (OAR) for anaplastic medulloblastoma, vulva cancer, tongue cancer, and advanced skin cancer. The time of treatment delivery in the case of a tomotherapy machine is comparable to the implementation of the plan prepared in intensity-modulated radiotherapy (IMRT) technique for a conventional linear accelerator. In the case of tomotherapy the application of a fractional dose was carried out in each case during one working period of the machine. For a conventional linear accelerator the total value of the fractional dose in the case of anaplastic medulloblastoma and metastases to bones was delivered using several treatment plans, for which a change of set-up was necessary during a fraction. CONCLUSION: The obtained results confirm that tomotherapy offers the possibility to obtain precise treatment plans together with the simplification of the therapeutic system.

9.
Pneumonol Alergol Pol ; 73(1): 76-8, 2005.
Artigo em Polonês | MEDLINE | ID: mdl-16539188

RESUMO

Two cases of pneumomediastinum were presented. Diagnosis was confirmed by plain chest X - ray and CT examination of the chest. None remarkable abnormality was found in a lung parenchyma or any other organs. Therefore the authors conclude that the direct cause of pneumomediastinum was psychostimulants administration--amphetamine. Typical treatment was successful.


Assuntos
Anfetamina/efeitos adversos , Alucinógenos/efeitos adversos , Enfisema Mediastínico/induzido quimicamente , Enfisema Mediastínico/diagnóstico por imagem , Adulto , Anfetamina/administração & dosagem , Alucinógenos/administração & dosagem , Humanos , Masculino , Radiografia Torácica
10.
Wiad Parazytol ; 50(1): 41-54, 2004.
Artigo em Polonês | MEDLINE | ID: mdl-16892604

RESUMO

The importance of demodicids (Demodex folliculorum and D. brevis) infestation and their effect on skin lesions has been described based on literature data and our own clinical and parasitological investigations. Hair follicle mites have been detected in 45% of patients with rosacea, 27% of patients with perioral dermatitis, 28% of patients suffering from seborrhoeic dermatitis and in 3 out of 7 patients with chronic blepharitis. Clinical picture of demodecosis included erythemato-papulous and pustulous (rosacea-like) skin lesions together with erythemato-desquamative changes of the face.


Assuntos
Blefarite/parasitologia , Dermatite Seborreica/parasitologia , Dermatoses Faciais/parasitologia , Folículo Piloso/parasitologia , Infestações por Ácaros/diagnóstico , Rosácea/parasitologia , Adolescente , Adulto , Idoso , Animais , Criança , Doença Crônica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
11.
Pol Merkur Lekarski ; 17(100): 407-9, 2004 Oct.
Artigo em Polonês | MEDLINE | ID: mdl-15690716

RESUMO

Due to appearance in the world scientific literature of reports on occurrence of pure red cell aplasia (PRCA) as an adverse effect of treatment with recombinant human erythropoietin administered for anemia correction in the course of chronic renal failure, the paper presents rules of diagnosis and treatment of this complication. PRCA is more frequently observed during subcutaneous administration of erythropoietin a than erythropoietin beta. According to currently available analysis, prophylaxis of PRCA may include changing of the route of erythropoietin alpha administration from subcutaneous to intravenous one.


Assuntos
Eritropoetina/administração & dosagem , Eritropoetina/efeitos adversos , Aplasia Pura de Série Vermelha/induzido quimicamente , Epoetina alfa , Humanos , Injeções Intravenosas , Injeções Subcutâneas , Proteínas Recombinantes , Aplasia Pura de Série Vermelha/diagnóstico , Aplasia Pura de Série Vermelha/terapia
12.
Adv Perit Dial ; 19: 246-50, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14763072

RESUMO

The aim of the present study was to establish a relationship between serum haptoglobin (HTG) concentration, peritoneal dialysis (PD) adequacy, and nutrition status in PD patients with and without diabetes. We measured serum concentrations of HTG, albumin, iron, and cholesterol; platelet count; transferrin saturation (TSAT); weekly Kt/V; and total weekly creatinine clearance (CCr) in 60 patients with and without diabetes who were being treated with continuous ambulatory PD or automated PD. The mean serum HTG concentration in PD patients without diabetes (2.5 +/- 1.2 g/L) was elevated and differed significantly from that in PD patients with diabetes (2.0 +/- 1.1 g/L). In patients without diabetes the correlation of serum HTG concentration with serum albumin level was r = -0.330 (p < 0.030), with platelet count was r = 0.320 (p < 0.040), with serum iron concentration was r = -0.450 (p < 0.002), with TSAT was r = -0.4200 (p < 0.005), and with age was r = 0.337 (p = 0.003). No such relationships were seen in patients with diabetes. In both subgroups, no dependence was seen between serum HTG concentration and weekly Kt/V, total weekly CCr, or serum cholesterol concentration. Serum HTG concentration in PD patients without diabetes may be a valid inflammatory marker. The HTG serum level displays a significant statistical dependence on age, platelet count, and markers of nutrition such as serum albumin level, iron, and TSAT. It does not depend on markers of dialysis adequacy (weekly Kt/V, total weekly CCr) or on serum cholesterol concentration. The serum HTG concentration in PD patients with diabetes is lower than that in patients without diabetes, and it is not related to examined factors of inflammation, nutrition, or adequacy of dialysis.


Assuntos
Nefropatias Diabéticas/sangue , Haptoglobinas/análise , Falência Renal Crônica/sangue , Estado Nutricional , Diálise Peritoneal , Adolescente , Adulto , Idoso , Colesterol/sangue , Creatinina/metabolismo , Nefropatias Diabéticas/terapia , Feminino , Humanos , Ferro/sangue , Falência Renal Crônica/terapia , Masculino , Pessoa de Meia-Idade , Diálise Peritoneal Ambulatorial Contínua , Contagem de Plaquetas , Albumina Sérica/análise , Transferrina/análise , Ureia/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...